Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

April 12, 2002

Slides

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Cozaar™ (losartan) in Type 2 Diabetes and Nephrophathy, Michael C. Elia, PhD, Merck Research Laboratories   ppt   htm